THE AUSTRALIAN DEFENCE FORCE ROWING CLUB AFFILIATED AT THE 53rd AGM

Rowing ACT is very pleased to announce that Member Clubs agreed in August to the affiliation of the Australian Defence Force Rowing Club (ADFRC).   The sport has been growing over time and any addition to the number of Member Clubs is a very welcome event.

Major Gary Bergman explained the reasons behind setting up the Club.

  • To ensure that all personnel (ADF, APS, Reservists, veterans, civilians) participating in rowing training or competition in our boats  when part of a composite crew are insured under Rowing Australia’s National Insurance Program.
  • To increase participation in rowing by ADF personnel whose service precludes or makes it difficult to justify a civilian club membership.
  • To enable ADF personnel to register and compete at broader range of Rowing Australia events without requiring a civilian club membership.
  • To facilitate the participation of ADF (composite) crews consisting of ADF personnel in a wider range of non-regatta events.
  • Becoming a member club will permit participation in targeted international military sports competitions and events. As a member club of Rowing ACT the ADF Rowing Club will be listed on Regatta Central, which provides a medium for contact and interaction between the military forces of other countries.

Gary also explained that the Australian Defence Force Rowing Association (ADFRA) will remain the peak body responsible to ADF Sports Council for promoting and developing rowing in the ADF.   ADFRA will administer and support the ADF, ADFA and RMC Rowing Clubs, as well as ADF Members of civilian rowing clubs.  There is no requirement for civilian rowing club members to change clubs.

Membership of the ADF Rowing Club will initially be limited to full time and Reserve ADF members. Affiliate/Associate membership will possibly be available for veteran personnel in the future.   Membership will not be available to members of the wider non-Defence community.

The ADF Sports Strategy 2015–2019 requires that all members of the ADF are provided every opportunity and encouraged to participate in sport at a level commensurate with their preference and ability.   With the ADF Rowing Club as an RA affiliated Club, an increase in active ADF personnel in rowing on a range of levels is expected, particularly in non-regatta events.

Gary said the Committee of the ADF Rowing Club looks forward to working with Rowing ACT, ACT Rowing clubs and ACT rowers to continue promoting and developing the sport.

The Invictus Games are very much in the spotlight at the moment.  ADF Rowing, in conjunction with Gordon Marcks who is the Senior Coach for Para-Rowing at Rowing Australia, have been supporting since January the 2017 Invictus Games selection camp for indoor rowing.  This included coaching the Canberra based Invictus Games indoor rowing athletes since that time.  Two athletes, Pilot Officer Nathan Parker and Lance Corporal Gary Wilson are currently competing in the 2017 Invictus Games.   ADF Rowing is currently planning to support a larger Indoor rowing contingent for the 2018 Invictus Games, which will be held in Sydney.

 

28 replies
  1. cjc-1295/ipamorelin side effects
    cjc-1295/ipamorelin side effects says:

    Tesamorelin Subcutaneous Route Side Effects & Dosage

    Research

    Scientific investigations into tesamorelin focus on its role in reducing abdominal adiposity among individuals
    with HIV-associated lipodystrophy. Randomized controlled trials have shown that once‑daily
    subcutaneous injections can lower visceral fat by up to
    20 % over a year, improving insulin sensitivity and lipid
    profiles. Pharmacokinetic studies confirm rapid absorption through the dermis,
    with peak serum levels reached within two hours of injection. Ongoing research also
    explores potential benefits for non‑HIV patients with metabolic syndrome, though data remain preliminary.

    Education

    Patients receiving tesamorelin should understand its
    mechanism: the drug mimics growth hormone‑releasing
    hormone (GHRH), stimulating pituitary secretion of growth hormone and subsequent
    release of insulin‑like growth factor‑1 (IGF‑1). This cascade targets visceral fat while sparing subcutaneous stores.

    Educational materials emphasize adherence, proper injection technique, and monitoring for adverse effects
    such as edema or arthralgia.

    Tesamorelin (subcutaneous route)

    The medication is administered by injecting a 2 mg solution into
    the abdomen, thigh, or upper arm. The needle size typically ranges from 25‑27 gauge, with a depth of 5–10 mm to reach the subcutaneous tissue.
    Patients should rotate sites daily and observe the injection area
    for redness or swelling.

    Brand Name

    The generic product is known as tesamorelin acetate; it is available
    under brand names that may vary by region.

    US Brand Name

    In the United States, the drug is marketed as Egrifta®.

    Description

    Egrifta® is a synthetic analog of GHRH. It is formulated
    as a sterile aqueous solution for subcutaneous injection, packaged in prefilled syringes
    containing 2 mg per dose. The product is refrigerated and protected from light
    until use.

    Before Using

    Prior to initiating therapy, patients should undergo baseline assessments:
    fasting glucose, insulin levels, lipid panel, liver function tests, and
    abdominal imaging (CT or MRI) to quantify visceral fat.
    A complete medical history, including previous growth hormone therapies, is
    essential.

    Allergies

    Individuals with known hypersensitivity to tesamorelin, any excipients, or other
    peptide medications should avoid use. Report allergic reactions such as rash, itching,
    or anaphylaxis immediately.

    Pediatric

    Tesamorelin has not been approved for pediatric use; clinical trials in children are ongoing.
    Off‑label administration requires careful evaluation by a specialist and
    parental consent.

    Geriatric

    Older adults may experience altered pharmacodynamics.
    Dose adjustments are generally unnecessary, but monitoring for
    edema, arthralgia, or impaired glucose tolerance is advised due to age‑related comorbidities.

    Breastfeeding

    No data support safety during lactation. Lactating mothers
    should discontinue therapy and consult a healthcare provider before resuming.

    Drug Interactions

    Co‑administration with insulin or oral hypoglycemics may potentiate hyperglycemia; blood glucose should be monitored closely.
    Growth hormone–stimulating agents, anabolic steroids,
    or medications that affect IGF‑1 levels can amplify effects or side reactions.

    Other Interactions

    Certain herbal supplements (e.g., ginseng) and high‑dose vitamin A
    may influence growth hormone pathways. Patients should disclose all over‑the‑counter products to their clinician.

    Other Medical Problems

    Conditions such as uncontrolled diabetes, active malignancy, severe hepatic impairment, or a history of pituitary
    disorders are contraindications or require strict monitoring.
    Individuals with chronic kidney disease should
    be evaluated for renal clearance impact.

    Proper Use

    Administer the injection once daily at the same
    time each day to maintain steady plasma concentrations.
    Avoid injecting into scar tissue or areas of infection. Keep the
    syringe capped between doses and dispose of needles safely in a sharps
    container.

    Dosing

    The standard dose is 2 mg subcutaneously once per day.
    Adjustments are not typically required; however, patients with significant weight loss
    or changes in body composition may benefit from reassessment after
    three months.

    Missed Dose

    If a dose is missed, inject as soon as remembered unless it is near the
    next scheduled time. Skip the missed dose rather than doubling up
    to compensate for an omitted injection.

    Storage

    Store Egrifta® refrigerated at 2–8 °C (36–46 °F).
    Do not freeze. Protect from light by keeping the vial in its original packaging.
    Once removed from refrigeration, the solution can remain stable at room temperature for up to
    30 minutes before use.

    Precautions

    Patients should be advised to monitor blood glucose regularly and report symptoms of
    swelling, joint pain, or new onset hypertension. Routine
    follow‑up visits every three months allow adjustment of therapy based on efficacy and tolerance.

    Side Effects

    cjc-1295/ipamorelin side effects effects are generally mild but
    can include:

    More common

    Injection site reactions (pain, redness, swelling)

    Peripheral edema

    Arthralgia or myalgia

    Headache

    Less common

    Hyperglycemia requiring antidiabetic medication adjustment

    Hypersensitivity reactions (rash, itching)

    Elevated triglycerides

    Mild nausea

    Products & Services

    Healthcare providers can obtain Egrifta® through licensed pharmacies.
    Some insurance plans cover the drug for qualifying patients with HIV‑associated
    lipodystrophy; prior authorization is often required.

    Advertising & Sponsorship

    Egrifta® marketing materials emphasize its efficacy in reducing visceral fat and improving metabolic markers.
    No external sponsorship influences clinical recommendations provided herein.

    Final days of 5X Challenge!

    Participants completing the final phase should consult their clinician for assessment of weight loss progress, adherence to therapy, and
    any necessary dose modifications. Celebrating milestones can improve motivation but should not replace routine medical oversight.

    About Mayo Clinic

    Mayo Clinic is a leading nonprofit organization dedicated to patient care, education, and research.

    Its experts contribute to evidence‑based guidelines on therapies such as tesamorelin.

    Medical Professionals

    Healthcare practitioners can access up‑to‑date prescribing
    information, monitoring protocols, and patient education resources through Mayo Clinic’s professional portals.

    Businesses

    Pharmaceutical distributors may collaborate with Mayo Clinic for product placement,
    educational campaigns, and clinical trial recruitment in accordance with
    ethical standards.

    Students

    Medical and pharmacy students can review case studies on tesamorelin usage within HIV‑associated
    lipodystrophy to enhance their understanding of endocrine therapy.

    Researchers

    Investigators studying metabolic disorders or growth
    hormone analogs may reference Mayo Clinic’s data repositories for preliminary findings and ongoing trials involving tesamorelin.

    International Patients

    Patients traveling abroad should verify the availability
    and regulatory status of Egrifta® in destination countries.
    Travel insurance that covers prescription medications can mitigate unexpected costs.

    Charitable Care & Financial Assistance

    Mayo Clinic offers financial counseling to patients facing medication affordability challenges.

    Pharmaceutical assistance programs may also provide discounted or free supplies
    for qualifying individuals.

    Follow Mayo Clinic

    Patients are encouraged to follow Mayo Clinic’s updates on new
    research, treatment guidelines, and patient support resources through
    newsletters or social media channels.

    Get the Mayo Clinic app

    The Mayo Clinic mobile application offers appointment scheduling, medication reminders, and access to
    educational content about tesamorelin and related therapies.

  2. dianabol anavar cycle results
    dianabol anavar cycle results says:

    The Heart Of The Internet

    The Heart Of The Internet

    In the digital age, the internet is often described as
    a vast network of interconnected systems and devices that facilitate communication, information exchange, and commerce across the globe.
    However, its true essence lies in the intricate layers of protocols, hardware, and software
    that work together seamlessly to deliver data from one
    point to another. Understanding this “heart” involves exploring how data travels
    through the internet’s infrastructure—an endeavor that reveals the
    complexity behind everyday browsing, streaming, and connectivity.

    —

    The Test of Connectivity

    One foundational aspect of the internet’s architecture is its ability
    to maintain reliable connections between countless devices.

    This reliability is assessed using various diagnostic
    tools such as ping, traceroute, and more advanced
    network monitoring solutions. These tests measure latency (the time
    it takes for data packets to travel from source to destination), packet
    loss, and route stability—critical factors that influence user experience.

    Ping and Latency

    Ping sends a small “echo request” packet to a target IP address.

    The response (“echo reply”) indicates round‑trip latency in milliseconds (ms).

    Lower ping values generally translate to smoother interactions for real‑time applications like gaming or VoIP.

    Traceroute and Path Analysis

    Traceroute maps the path packets take through intermediate routers.

    It displays hop count, each router’s IP address, and associated latency.

    Identifying high‑latency hops helps network administrators pinpoint
    bottlenecks.

    These basic tools are essential for troubleshooting connectivity issues or optimizing performance across
    networks.

    5. Network Monitoring – Tools

    Monitoring is essential to maintain uptime, detect anomalies, and ensure security compliance.
    Below is a curated list of popular monitoring solutions that can be integrated into most environments:

    Tool Type Key Features Typical Use

    Nagios Core Open‑source Host/Service checks, alerting, plugin architecture Comprehensive infrastructure monitoring

    Zabbix Open‑source Agent & SNMP monitoring, auto‑discovery, real‑time graphs Enterprise‑level monitoring with dashboards

    Prometheus + Grafana Open‑source Time‑series database, pull model,
    powerful query language, alerting rules Metrics collection from cloud/native apps

    Datadog SaaS Cloud agent, log & metric aggregation, APM, AI alerts Unified monitoring for microservices

    Dynatrace SaaS Full‑stack observability, automatic instrumentation, AI
    root‑cause analysis Enterprise performance management

    New Relic SaaS Synthetic tests, real‑user monitoring, distributed tracing Full‑stack application performance

    —

    3. Observability – What, How & Why

    Category Typical Data Collection Method Tool Example(s) Key Questions Answered

    Metrics CPU, memory, request latency, error rates, queue
    depth, DB connections Push (e.g., Prometheus node_exporter), Pull (Prometheus scrapes exporters) Prometheus, InfluxDB + Grafana “What is the load? Are we saturating resources?”

    Logs Request/response traces, error stack traces, debug messages Centralized log shipper (Fluentd,
    Logstash) → Elasticsearch or Loki ELK stack, Loki “Why did a request fail? Where in code?”

    Traces Span IDs linking microservice calls, span durations Distributed tracing collector
    (Jaeger, Zipkin) Jaeger UI, Zipkin UI “Which service is causing latency? Is there a bottleneck?”

    —

    3. Choosing an Observability Stack

    A. Open‑Source & Cloud‑Native Path

    Component Purpose Popular Implementations

    Metric Collection Collect CPU, memory, custom counters Prometheus +
    Node Exporter (or cAdvisor)

    Visualization / Alerting Dashboards, query language, alerts Grafana (with Prometheus data source), Alertmanager

    Tracing Distributed tracing across services Jaeger (OpenTelemetry collector) or Zipkin

    Logging Central log aggregation and search Loki + Promtail or Elasticsearch + Fluentd

    Pros: Fully controllable, open‑source, no vendor lock‑in.

    Cons: Requires operational overhead to deploy/maintain.

    3.2 Commercial SaaS Solutions

    Datadog

    – Agent collects metrics, logs, traces; integrates with many
    languages out of the box.
    – Unified UI; auto‑instrumentation for common frameworks
    (Spring, Node.js, .NET).
    – Cost: ~USD 0.15 per host/month + log ingestion fees.

    New Relic One

    – Offers APM, Infrastructure monitoring, Synthetics,
    Logs in a single platform.
    – Auto‑discovery of services; deep transaction traces.

    – Cost: Per-host or per-licensing model (~USD 20–30 per
    host/month).

    Datadog

    – Agent collects metrics + traces; integrates with Kubernetes dashboards.

    – Log collection via forwarders (Fluent Bit, Fluentd).

    – Cost: ~USD 15 per host/month + log ingestion fees.

    Elastic Stack (ELK) + APM

    – Open‑source option; requires self‑hosting and scaling.

    – Elastic APM collects traces; Kibana visualizes dashboards.

    – Cost: Infrastructure cost only; optional commercial subscriptions
    for support.

    —

    5. Suggested Monitoring Stack for the Current Kubernetes Cluster

    Component Role Why it fits

    Prometheus + Node Exporter / kubelet exporter Metrics collection (CPU,
    memory, network, disk I/O) Native to Kubernetes; easy to scale horizontally; integrates with Grafana.

    Alertmanager Alert routing & silencing Built‑in with Prometheus;
    supports Slack/Email/Webhooks for notifications.

    Grafana Dashboards Connects directly to Prometheus; pre‑built Kubernetes dashboards
    available.

    cAdvisor (via kubelet) Container-level metrics Already exposed by kubelet; provides CPU/memory usage per container.

    Jaeger / Zipkin Distributed tracing Optional for microservices; helps identify latency bottlenecks.

    ELK Stack or Loki Log aggregation (optional) For centralized log collection and correlation with metrics.

    2.2 Implementation Steps

    Deploy Prometheus Operator

    – Install the operator using Helm chart `prometheus-community/kube-prometheus-stack`.

    – This will create:
    – Prometheus server
    – Alertmanager
    – ServiceMonitors for core components (kube-apiserver, kube-controller-manager, kube-scheduler,
    etc.)
    – Grafana with pre‑configured dashboards.

    Configure Scrape Targets

    – Use existing ServiceMonitors to scrape metrics from all
    control plane nodes.
    – Ensure `kubelet` service monitor is enabled to collect node
    level metrics (CPU, memory).

    Set Up Alerting Rules

    – Define Prometheus alert rules for:
    – High CPU usage on controller nodes
    – Low available memory
    – API server request latency > threshold
    – etc.
    – Export alerts via Alertmanager to email or
    PagerDuty.

    Grafana Dashboards

    – Import dashboards from the Grafana community (e.g.,
    “Kubernetes Cluster Monitoring”).
    – Customize to include:
    – Control plane node CPU/memory usage
    – API server latency and request counts
    – Pod status distribution

    Testing

    – Simulate load on API server using `kubectl run` with multiple pods.

    – Verify metrics update correctly.

    —

    4. Final Summary

    Objective: Monitor CPU usage of control plane nodes and gather overall cluster statistics.

    Solution:

    Deploy Node Exporter on each node (via DaemonSet).

    Expose node metrics to Prometheus using ServiceMonitor.

    Configure Prometheus to scrape these metrics.

    Create dashboards in Grafana or use PromQL queries for custom analysis.

    Result: Continuous visibility into CPU load on control
    plane nodes and the entire cluster, enabling proactive scaling
    and troubleshooting.

    This plan ensures a robust, scalable monitoring setup that can be extended
    with other metrics (memory, network, disk) as needed.

    References:

    dianabol anavar cycle results

Comments are closed.